You are here

We are astonished at the current lack of attention to osteoarthritis”. Correo Farmacéutico interviews Josep Escaich

21 Oct 2011
Bioiberica

The general manager of Bioiberica highlighted his company’s commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients’ quality of life.

Correo Farmacéutico devoted his weekly "Companies" section to Bioibérica. In an interview given to this specialized newspaper, Josep Escaich, Bioiberica´s general director, analyzed the current crisis in the pharmaceutical sector and highlighted the need of searching for new opportunities and to adapt ourselves to the new rules of play. Moreover, Escaich defended Bioiberica Farma’s comprehensive approach to osteoarthritis as the right strategy to improve the patients’ quality of life.


For further information, go to:
http://www.correofarmaceutico.com/2011/10/17/farmacologia/estamos-estupefactos-ante-el-desamparo-en-artrosis

http://www.correofarmaceutico.com/2011/10/17/farmacologia/debemos-aceptar-las-nuevas-reglas-del-juego-y-buscar-oportunidades-entre-ellas

Related News

14 Apr 2025
Bioiberica

As Bioiberica celebrates its 50th anniversary, Luis Solera, CEO reflects on the company’s evolution—from a pioneer in heparin production to a global leader in the biotech industry.

Bioiberica